无创呼吸机联合乙酰半胱氨酸治疗伴Ⅱ型呼吸衰竭COPD患者的价值分析

摘要
图/表
参考文献(17)
相关文章 (1)

全文:PDF(1884 KB)HTML(1 KB)
输出:BibTeX|EndNote(RIS)

摘要目的：探讨对伴有Ⅱ型呼吸衰竭慢性阻塞性肺疾病（chronic obstructive pulmonary disease,COPD）患者予无创呼吸机通气联合乙酰半胱氨酸（N-acetyl cysteine,NAC）溶液雾化吸入治疗的临床价值。方法：将我院2020年5月―2022年1月收治的169例COPD合并Ⅱ型呼吸衰竭（respiratory failure,RF）患者以随机数字表法分为对照组84例和观察组85例,对照组予常规治疗联合无创通气治疗,观察组在对照组基础上予NAC溶液雾化吸入治疗,为期7 d。观察两组临床疗效、治疗前后血气指标、呼吸力学变化及肺功能情况。结果：与对照组88.10%的总有效率相比,观察组97.65%的总有效率更高。治疗7 d后,与对照组氧分压（PaO₂）、pH值及氧饱和度（SpO₂）相比,观察组更高;与对照组二氧化碳分压（PaCO₂）相比,观察组更低。与对照组潮气量（VT）、吸气时间分数（Ti/Ttot）相比,观察组更高;与对照组呼吸频率（RR）相比,观察组更低;与对照组1 s用力呼气量（FEV1）、用力肺活量（FVC）及最大通气量（MVV）相比,观察组更高。结论：无创呼吸机通气联合NAC溶液雾化吸入能够提高临床疗效,有效改善COPD合并Ⅱ型RF患者血气指标、呼吸力学指标及肺功能。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	马春梅
	段玲
	杜晶
	李红永

关键词：无创呼吸机,乙酰半胱氨酸,雾化吸入,Ⅱ型呼吸衰竭,慢性阻塞性肺疾病

Abstract：ObjectiveTo explore the clinical value of non-invasive ventilator ventilation combined with acetylcysteine (NAC) solution aerosol inhalation on patients with type II respiratory failure (RF) complicated with chronic obstructive pulmonary disease (COPD).Methods169 patients with COPD complicated with type II RF who were treated in the hospital from May 2020 to January 2022 were divided into the control group (84 cases) and the observation group (85 cases) according to the random number table method. The control group was given conventional treatment combined with non-invasive ventilation, while the observation group was treated with NAC solution for aerosol inhalation on the basis of the control group, and both groups were treated for 7 days. The clinical efficacy, as well as blood gas indicators, respiratory mechanics changes and pulmonary function before and after treatment were observed in the two groups.ResultsThe total effective rate was 97.65% in the observation group, which was higher than 88.10% in the control group. After 7 days of treatment, the partial pressure of oxygen (PaO₂), PH value and oxygen saturation (SpO₂₎in the observation group were higher while the partial pressure of carbon dioxide (PaCO₂) was lower compared to the control group. The tidal volume (VT) and fractional inspiratory time (Ti/Ttot) were higher while the respiratory rate (RR) was lower in the observation group compared to the control group. The forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and maximum ventilation volume (MVV) in the observation group were higher than those in the control group.ConclusionNon-invasive ventilator ventilation combined with aerosol inhalation of NAC solution can enhance the clinical efficacy, and effectively improve the blood gas indicators, respiratory mechanics indicators and pulmonary function in patients with COPD and type II RF.

Key words：non-invasive ventilator acetylcysteine aerosol inhalation type II respiratory failure chronic obstructive pulmonary disease

收稿日期:2023-04-14

中图分类号:

R563.8

基金资助:四川省科技厅科研课题（2023NSFSC0742）

通讯作者:李红永,E-mail：286859186@qq.com

引用本文:

马春梅, 段玲, 杜晶, 李红永. 无创呼吸机联合乙酰半胱氨酸治疗伴Ⅱ型呼吸衰竭COPD患者的价值分析[J]. 金宝搏官方188学报(医学版), 2023, 20(3): 84-87. MA Chunmei, DUAN Ling, DU Jing, LI Hongyong. Value of non-invasive ventilator combined with acetylcysteine in the treatment of patients with type II respiratory failure and COPD. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 84-87.

链接本文:

http://yxb.hunnu.edu.cn/CN/或http://yxb.hunnu.edu.cn/CN/Y2023/V20/I3/84

[1] 杨双嘉, 邝敏, 邓嘉宁, 等. 噻托溴铵联合无创正压通气对慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者症状评分、肺功能及血气分析指标的影响[J]. 广西医科大学学报, 2020, 37(1): 61-67.
[2] Shi T, Feng L.Blood biomarkers associated with acute type II respiratory failure in COPD: A meta-analysis[J]. Clin Respir J, 2022, 16(2): 75-83.
[3] 吴爽, 王宏君, 陈琛, 等. 通腑益气平喘汤联合西药对慢性阻塞性肺疾病急性发作合并呼吸衰竭患者血气状态及机体微炎症反应的影响[J]. 陕西中医, 2020, 41(12): 1735-1738.
[4] 杨少敏, 刘芝芳. 纳美芬联合无创正压机械通气治疗老年COPD合并重症Ⅱ型呼吸衰竭的疗效及对患者血清人Clara细胞分泌蛋白、巨噬细胞刺激蛋白水平的影响研究[J]. 贵州医药, 2021, 45(4): 516-518.
[5] 杨慧亮, 李颖, 巴晓彤. 时间控制通气模式对COPD合并Ⅱ型呼吸衰竭患者血气分析和呼吸力学指标的影响[J]. 临床和实验医学杂志, 2020, 19(18): 1937-1940.
[6] 令狐秀萍. 乙酰半胱氨酸溶液雾化吸入治疗慢性阻塞性肺疾病的临床研究[J]. 中国药物与临床, 2021, 21(13): 2310-2312.
[7] 吴文婷, 梅益枝, 胡小芳. 无创呼吸机通气联合乙酰半胱氨酸溶液吸入治疗老年呼吸衰竭合并高碳酸血症的效果及安全性[J]. 解放军医药杂志, 2022, 34(9): 29-33.
[8] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南 (2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
[9] 孙蕾艳, 程帆. 多沙普仑联合BiPAP无创呼吸机治疗COPD并Ⅱ型呼吸衰竭疗效及对血清PARC/CCL18的影响[J]. 中国临床研究, 2018, 31(8): 1047-1050.
[10] 江美芳, 刘蔺, 秦克. 噻托溴铵联合无创呼吸机治疗COPD合并Ⅱ型呼吸衰竭疗效及对患者血气指标和炎症因子的影响[J]. 标记免疫分析与临床, 2020, 27(1): 132-135+141.
[11] 李若曈, 饶蓁蓁, 傅晏红, 等.2030年中国慢性阻塞性肺疾病的疾病负担预测与危险因素控制效果模拟[J]. 中华流行病学杂志, 2022, 43(2): 201-206.
[12] 杜锦辉, 陈芳. BiPAP无创呼吸机治疗慢性阻塞性肺疾病并Ⅱ型呼吸衰竭50例临床研究[J]. 陕西医学杂志, 2020, 49(7): 824-826+865.
[13] 王娜, 李强, 徐闻, 等. 无创机械通气治疗对老年COPD伴呼吸衰竭患者α-HBDH、β-EP、MMP-9及TIMP-1的影响[J]. 武警医学, 2020, 31(4): 296-298.
[14] 郝文东, 王国芳, 张彩莲, 等. N-乙酰半胱氨酸联合双水平气道正压通气治疗AE-COPD合并Ⅱ型呼吸衰竭的疗效及作用机制研究[J]. 现代中西医结合杂志, 2018, 27(7): 724-727.
[15] Teng W, Chen H, Shi S, et al.Effect of bilevel continuous positive airway pressure for patients with type II respiratory failure due to acute exacerbation of COPD: A protocol for systematic review and meta-analysis[J]. Medicine (Baltimore), 2021, 100(2): e24016.
[16] 李英明, 郑冉冉, 谢丰建. 无创呼吸机联合N-乙酰半胱氨酸治疗急性呼吸衰竭患者的疗效观察[J]. 国际检验医学杂志, 2021, 42(13): 1639-1641.
[17] 杨宝春, 王丽东, 孙欣. 乙酰半胱氨酸胶囊联合双水平无创正压通气治疗AECOPD合并Ⅱ型呼吸衰竭观察[J]. 中国药师, 2020, 23(3): 485-487.